BD names Peter Menziuso president of interventional unit – Image for illustrative purposes only (Image credits: Unsplash)
BD has selected a veteran healthcare executive with more than three decades of experience to lead its interventional business. The move comes as the company seeks to build on recent performance in a competitive medical technology sector. Peter Menziuso will assume the role of executive vice president and president of BD Interventional on June 1.
Strategic Appointment at a Critical Time
The announcement positions Menziuso to guide a portfolio that includes devices and solutions used in minimally invasive procedures. BD described the unit as having delivered consistent results in recent periods. Company leaders view the hire as a way to sustain that momentum through focused execution and customer-driven innovation.
Menziuso joins from Johnson & Johnson Vision, where he served as company group chairman. In that role he oversaw a roughly $5 billion global operation spanning commercial activities, research and development, supply chain, quality, finance and medical affairs.
Extensive Background in Healthcare Growth
Throughout his career Menziuso has held senior positions that emphasized market expansion and operational discipline. He previously led commercial efforts in cardiovascular and metabolism products at Janssen, helping transform a multi-billion-dollar business during a period of dynamic growth. His experience also includes leadership in vision care at both the U.S. and worldwide levels.
BD highlighted Menziuso’s ability to strengthen market positions, assemble high-performing teams and convert strategy into measurable outcomes. These skills are expected to support continued advancement across the interventional portfolio.
CEO Highlights Leadership Fit
Tom Polen, chairman, chief executive officer and president of BD, welcomed the appointment. “BD Interventional has a strong track record of performance, and Peter is the right leader to build on that momentum and continue delivering results,” Polen said. He added that Menziuso combines strategic oversight with operational discipline and a focus on customers and patients.
The comments underscore BD’s emphasis on disciplined growth and portfolio strength. Menziuso’s global perspective and customer focus are seen as assets for navigating evolving clinical needs and competitive pressures.
Broader Context for BD
BD operates as one of the world’s largest pure-play medical technology companies. Its purpose centers on advancing health through innovation in medical essentials, connected care, biopharma systems and interventional solutions. The company employs more than 60,000 people worldwide and delivers billions of products each year.
With the leadership transition now set, attention turns to how Menziuso will shape priorities in the interventional segment. The appointment reflects BD’s ongoing effort to align experienced executives with key growth areas.
